Schildhaus, Hans-Ulrich

[["dc.bibliographiccitation.journal","Oncology Research and Treatment"],["dc.bibliographiccitation.volume","39"],["dc.contributor.author","Jo, Peter"],["dc.contributor.author","Kitz, Julia"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Azizian, A."],["dc.contributor.author","Bernhardt, M."],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Schirmer, Markus Anton"],["dc.contributor.author","Koenig, A."],["dc.contributor.author","Grade, Marian"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Stroebel, Philipp"],["dc.contributor.author","Schildhaus, Hans-Ulrich"],["dc.contributor.author","Gaedcke, Jochen"],["dc.date.accessioned","2018-11-07T10:20:53Z"],["dc.date.available","2018-11-07T10:20:53Z"],["dc.date.issued","2016"],["dc.format.extent","75"],["dc.identifier.isi","000371353700239"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/41971"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Karger"],["dc.publisher.place","Basel"],["dc.relation.issn","2296-5262"],["dc.relation.issn","2296-5270"],["dc.title","Heterogeneity of KRAS Mutation Status in Rectal Cancer"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","158"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Case Reports in Oncology"],["dc.bibliographiccitation.lastpage","163"],["dc.bibliographiccitation.volume","9"],["dc.contributor.author","Overbeck, Tobias R."],["dc.contributor.author","Schmitz, Katja"],["dc.contributor.author","Engelke, Christoph"],["dc.contributor.author","Sahlmann, Carsten-Oliver"],["dc.contributor.author","Hugo, Sara"],["dc.contributor.author","Kellner, Laura"],["dc.contributor.author","Trümper, Lorenz"],["dc.contributor.author","Schildhaus, Hans-Ulrich"],["dc.date.accessioned","2020-12-10T18:37:47Z"],["dc.date.available","2020-12-10T18:37:47Z"],["dc.date.issued","2016"],["dc.identifier.doi","10.1159/000444745"],["dc.identifier.eissn","1662-6575"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/77092"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Partial Response to First-Line Crizotinib in an Elderly Male Patient with ROS1 Translocation-Positive Lung Cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","3028"],["dc.bibliographiccitation.issue","15_suppl"],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.lastpage","3028"],["dc.bibliographiccitation.volume","34"],["dc.contributor.author","Scheel, Andreas H."],["dc.contributor.author","Dietel, Manfred"],["dc.contributor.author","Heukamp, Lukas C."],["dc.contributor.author","Jöhrens, Korinna"],["dc.contributor.author","Kirchner, Thomas"],["dc.contributor.author","Reu, Simone"],["dc.contributor.author","Ruschoff, Josef"],["dc.contributor.author","Schildhaus, Hans-Ulrich"],["dc.contributor.author","Schirmacher, Peter"],["dc.contributor.author","Tiemann, Markus"],["dc.contributor.author","Warth, Arne"],["dc.contributor.author","Weichert, Wilko"],["dc.contributor.author","Fischer, Rieke Nila"],["dc.contributor.author","Wolf, Juergen"],["dc.contributor.author","Buettner, Reinhard"],["dc.date.accessioned","2020-12-10T18:41:30Z"],["dc.date.available","2020-12-10T18:41:30Z"],["dc.date.issued","2016"],["dc.identifier.doi","10.1200/JCO.2016.34.15_suppl.3028"],["dc.identifier.eissn","1527-7755"],["dc.identifier.issn","0732-183X"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/77597"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Diagnostic PD-L1 immunohistochemistry in NSCLC: Results of the first German harmonization study."],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","3031"],["dc.bibliographiccitation.issue","15_suppl"],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.lastpage","3031"],["dc.bibliographiccitation.volume","34"],["dc.contributor.author","Schildhaus, Hans-Ulrich"],["dc.contributor.author","Richardt, Pascal"],["dc.contributor.author","Wilsberg, Lea"],["dc.contributor.author","Schmitz, Katja"],["dc.date.accessioned","2020-12-10T18:41:30Z"],["dc.date.available","2020-12-10T18:41:30Z"],["dc.date.issued","2016"],["dc.identifier.doi","10.1200/JCO.2016.34.15_suppl.3031"],["dc.identifier.eissn","1527-7755"],["dc.identifier.issn","0732-183X"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/77598"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Occurrence of PDL1/2 copy number gains detected by FISH in adeno and squamous cell carcinomas of the lung and association with PDL1 overexpression in adenocarcinomas."],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Frontiers in Pediatrics"],["dc.bibliographiccitation.volume","6"],["dc.contributor.author","Ragab, Nada"],["dc.contributor.author","Viehweger, Florian"],["dc.contributor.author","Bauer, Julia"],["dc.contributor.author","Geyer, Natalie"],["dc.contributor.author","Yang, Mingya"],["dc.contributor.author","Seils, Anna"],["dc.contributor.author","Belharazem, Djeda"],["dc.contributor.author","Brembeck, Felix H."],["dc.contributor.author","Schildhaus, Hans-Ulrich"],["dc.contributor.author","Marx, Alexander"],["dc.contributor.author","Hahn, Heidi"],["dc.contributor.author","Simon-Keller, Katja"],["dc.date.accessioned","2020-12-10T18:44:36Z"],["dc.date.available","2020-12-10T18:44:36Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.3389/fped.2018.00378"],["dc.identifier.eissn","2296-2360"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/78522"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Canonical WNT/β-Catenin Signaling Plays a Subordinate Role in Rhabdomyosarcomas"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","126"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Der Pathologe"],["dc.bibliographiccitation.lastpage","136"],["dc.bibliographiccitation.volume","36"],["dc.contributor.author","Schmitz, Katja"],["dc.contributor.author","Schildhaus, H.-U."],["dc.date.accessioned","2018-11-07T10:00:00Z"],["dc.date.available","2018-11-07T10:00:00Z"],["dc.date.issued","2015"],["dc.description.abstract","Soft tissue tumors are often challenging for pathologists on the basis of morphology alone; therefore, tumor-specific chromosomal aberrations, such as translocations and fusions, amplifications or deletions can be diagnostically useful. Fluorescence in situ hybridization is widely used for the detection of most aberrations in routine diagnostics. Furthermore, reverse transcriptase PCR, sequencing and specific immunohistochemical assays are also applied. Next generation sequencing has already contributed to the identification of hitherto unknown aberrations. Molecular pathology is mainly used in sarcomas to discriminate between different tumor entities. In terms of personalized therapy and targeted treatment, molecular pathology can be utilized to detect predictive markers."],["dc.identifier.doi","10.1007/s00292-015-0010-6"],["dc.identifier.isi","000353059300002"],["dc.identifier.pmid","25822596"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/37709"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","1432-1963"],["dc.relation.issn","0172-8113"],["dc.title","Molecular pathology of soft tissue tumors: Contribution to diagnosis and therapy prediction"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","769"],["dc.bibliographiccitation.issue","9"],["dc.bibliographiccitation.journal","Immunotherapy"],["dc.bibliographiccitation.lastpage","782"],["dc.bibliographiccitation.volume","11"],["dc.contributor.author","Schiwitza, Annett"],["dc.contributor.author","Schildhaus, Hans-Ulrich"],["dc.contributor.author","Zwerger, Birgit"],["dc.contributor.author","Rüschoff, Josef"],["dc.contributor.author","Reinhardt, Christian"],["dc.contributor.author","Leha, Andreas"],["dc.contributor.author","Andreas, Stefan"],["dc.contributor.author","Rittmeyer, Achim"],["dc.date.accessioned","2020-12-10T18:43:39Z"],["dc.date.available","2020-12-10T18:43:39Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.2217/imt-2019-0039"],["dc.identifier.eissn","1750-7448"],["dc.identifier.issn","1750-743X"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/78202"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Monitoring efficacy of checkpoint inhibitor therapy in patients with non-small-cell lung cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1630"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Modern Pathology"],["dc.bibliographiccitation.lastpage","1644"],["dc.bibliographiccitation.volume","31"],["dc.contributor.author","Koppel, Christina"],["dc.contributor.author","Schwellenbach, Helena"],["dc.contributor.author","Zielinski, Dirk"],["dc.contributor.author","Eckstein, Sina"],["dc.contributor.author","Martin-Ortega, Mercedes"],["dc.contributor.author","D’Arrigo, Corrado"],["dc.contributor.author","Schildhaus, Hans-Ulrich"],["dc.contributor.author","Rüschoff, Josef"],["dc.contributor.author","Jasani, Bharat"],["dc.date.accessioned","2020-12-10T18:09:36Z"],["dc.date.available","2020-12-10T18:09:36Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1038/s41379-018-0071-1"],["dc.identifier.eissn","1530-0285"],["dc.identifier.issn","0893-3952"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/73702"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Optimization and validation of PD-L1 immunohistochemistry staining protocols using the antibody clone 28-8 on different staining platforms"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","6105"],["dc.bibliographiccitation.issue","23"],["dc.bibliographiccitation.journal","Clinical Cancer Research"],["dc.bibliographiccitation.lastpage","6116"],["dc.bibliographiccitation.volume","20"],["dc.contributor.author","Wozniak, Agnieszka"],["dc.contributor.author","Rutkowski, Piotr"],["dc.contributor.author","Schoffski, Patrick"],["dc.contributor.author","Ray-Coquard, Isabelle"],["dc.contributor.author","Hostein, Isabelle"],["dc.contributor.author","Schildhaus, Hans-Ulrich"],["dc.contributor.author","Le Cesne, Axel"],["dc.contributor.author","Bylina, Elzbieta"],["dc.contributor.author","Limon, Janusz"],["dc.contributor.author","Blay, Jean-Yves"],["dc.contributor.author","Siedlecki, Janusz A."],["dc.contributor.author","Wardelmann, Eva"],["dc.contributor.author","Sciot, Raf"],["dc.contributor.author","Coindre, Jean-Michel"],["dc.contributor.author","Debiec-Rychter, Maria"],["dc.date.accessioned","2018-11-07T09:31:58Z"],["dc.date.available","2018-11-07T09:31:58Z"],["dc.date.issued","2014"],["dc.description.abstract","Purpose: Although the mutational status in gastrointestinal stromal tumors (GIST) can predict the response to treatment with tyrosine kinase inhibitors, the role of tumor genotype as a prognostic factor remains controversial. The ConticaGIST study sought to determine the pathologic and molecular factors associated with disease-free survival (DFS) in patients with operable, imatinib-naive GIST. Experimental Design: Clinicopathologic and molecular data from 1,056 patients with localized GIST who underwent surgery with curative intention (R0/R1) and were registered in the European ConticaGIST database were prospectively obtained and reviewed. Risk of tumor recurrence was stratified using the modified NIH criteria. The median follow-up was 52 months. Results: On testing for potential prognostic parameters, the following were associated with inferior DFS on multivariable Cox model analysis: primary nongastric site, size > 10 cm, mitotic index > 10 mitoses per 50 high power field, and the KIT exon 9 duplication [hazard ratio (HR), 1.47; 95% confidence interval (CI), 0.9-2.5; P = 0.037] and KIT exon 11 deletions involving codons 557 and/or 558 [KITdel-inc557/558; HR, 1.45; 95% CI, 1.0-2.2; P = 0.004]. Conversely, PDGFRA exon 18 mutations were indicators of better prognosis [HR, 0.23; 95% CI, 0.1-0.6; P = 0.002]. KITdel-inc557/558 were an adverse indicator only in GIST localized in the stomach (P < 0.001) but not in tumors with nongastric origin. In gastric GIST, all other mutations presented remarkably superior 5-year DFS. Conclusions: In conclusion, tumor genotype is an independent molecular prognostic variable associated with gastric GIST and should be used for optimizing tailored adjuvant imatinib treatment. (C) 2014 AACR."],["dc.identifier.doi","10.1158/1078-0432.CCR-14-1677"],["dc.identifier.isi","000346417400027"],["dc.identifier.pmid","25294914"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/31643"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Assoc Cancer Research"],["dc.relation.issn","1557-3265"],["dc.relation.issn","1078-0432"],["dc.title","Tumor Genotype Is an Independent Prognostic Factor in Primary Gastrointestinal Stromal Tumors of Gastric Origin: A European Multicenter Analysis Based on ConticaGIST"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Oncology Research and Treatment"],["dc.bibliographiccitation.volume","37"],["dc.contributor.author","Nogova, L."],["dc.contributor.author","Gardizi, Masyar"],["dc.contributor.author","Bos, M."],["dc.contributor.author","Scheffler, M."],["dc.contributor.author","Papachristou, I."],["dc.contributor.author","Woempner, C."],["dc.contributor.author","Heukamp, Lukas Carl"],["dc.contributor.author","Schildhaus, H.-U."],["dc.contributor.author","Fuhr, Uwe"],["dc.contributor.author","Sos, Martin L."],["dc.contributor.author","Eberhardt, W."],["dc.contributor.author","Wiesweg, Marcel"],["dc.contributor.author","Schmid, Kurt Werner"],["dc.contributor.author","Schuler, M."],["dc.contributor.author","Thomas, Roman K."],["dc.contributor.author","Buettner, Reinhardt"],["dc.contributor.author","Wolf, J."],["dc.date.accessioned","2018-11-07T09:44:10Z"],["dc.date.available","2018-11-07T09:44:10Z"],["dc.date.issued","2014"],["dc.format.extent","92"],["dc.identifier.isi","000332306700296"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/34334"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Karger"],["dc.publisher.place","Basel"],["dc.relation.issn","2296-5262"],["dc.relation.issn","2296-5270"],["dc.title","TRY: A phase II study to evaluate safety and efficacy of combined trastuzumab and AUY922 in advanced non-small-cell lung cancer (NSCLC) with HER2 overexpression or amplification or mutation."],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]